ArticleMedical oncology (Northwood, London, England)2026
A novel matrine derivative exerts antitumor effects against hepatocellular carcinoma by inducing oxidative stress and DNA damage.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA has long been a major target in the development of anticancer drugs. Natural products, as an important source of antitumor agents, play a key role in cancer prevention and treatment. Matrine is a natural quinoline alkaloid isolated from the medicinal plant Sophora flavescens. In this study, using matrine as a lead compound, we designed and synthesized 25 novel matrine derivatives containing a naphthalimide moiety based on a molecular hybridization strategy. The antiproliferative activities of these derivatives were evaluated against several human cancer cell lines (Hela, A549, HepG2 and MHCC97H) and a normal human hepatocyte line (LO2). Results showed that most derivatives exhibited significantly enhanced antiproliferative activity compared to matrine. Among them, compound 15 h demonstrated the most potent effect, with an IC₅₀ value of 4.92 ± 0.33 µM against MHCC97H cells. Further mechanistic studies revealed that 15 h can effectively intercalate into and bind to DNA, significantly inhibit colony formation and migration of tumor cells, arrest the cell cycle at the G0/G1 phase, and induce apoptosis in a dose-dependent manner. In addition, 15 h promoted the accumulation of intracellular reactive oxygen species (ROS). Upregulation of γ-H2AX, a key DNA damage marker, was confirmed by both immunofluorescence and Western blot analysis, indicating that the antitumor activity of 15 h is closely associated with the induction of DNA damage. In conclusion, compound 15 h effectively suppresses tumor cell proliferation and induces apoptosis through ROS-mediated DNA damage, demonstrating promising potential for development as a novel DNA-targeting anticancer agent.
Indexed as
Identifiers
41838302What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.